CareDx reported total Q4 revenue of $108 million, marking a 25% increase over the prior year. Testing services revenue climbed 23% to $78 million, with volume up 17% to approximately 53,000 tests. Patient and digital solutions revenue rose 47% to $16.8 million and product revenue increased 17% to $13.3 million. GAAP net loss was $4 million, driven by $7 million in non-executive compensation expenses, while adjusted EBITDA reached $7 million.

Full-year revenue totaled $380 million, up 14% from 2024, including $275 million in testing services (10% growth) and 200,000 tests processed (14% growth). Patient and digital solutions revenue grew 31% to $57 million, and product revenue increased 19% to $48 million. The company logged a GAAP net loss of $21 million versus a prior-year net income, with non-GAAP net income of $32 million and adjusted EBITDA of $32 million. Cash flow from operations was $42 million and year-end cash and equivalents stood at approximately $200 million.

CareDx projects full-year 2026 revenue between $420 million and $444 million, reflecting continued momentum in testing services and digital solutions. The company repurchased $12 million of shares in Q4 at an average price of $15.79 and $88 million for the full year at $15.16 per share. Recent initiatives include rolling out an ImmuneScape multiomics platform in collaboration with 10x Genomics and validating AlloHeme™ data to expand into cell therapy diagnostics. Epic Aura integrations now live at seven transplant centers, with twenty more underway to streamline clinical workflows.